drugset / Trial / NCT04940845

Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults

NCT04940845

Phase 1 Unknown 174 enrolled Shanghai Hansoh Biomedical Co., Ltd
RandomizedParallel-groupSingle-blindPrevention

Summary

A randomized, single-blind and parallel group study to compare the pharmacokinetic, safety and immunogenicity of HS-20090-2 60mg#1ml#and Prolia® in healthy adults.

Timeline

Start
2021-07-26
Primary completion
2022-06
Completion
2022-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Denosumab Monoclonal antibody 60 mg Subcutaneous
Subject HS-20090-2 Unknown 60 mg Subcutaneous